IMVT
NASDAQ
$39.92
Immunovant Inc (IMVT)
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $47.19 (+18.21%)
Market Cap
$8.13B
FCF 5Y CAGR
+37.28%
Free Cash Flow Yield
-5.01%
Beta (5Y)
1.21
Price Chart
Valuation
Market Cap$8.13B
P/B9.34
Profitability
EBITDA-$505M
EPS-$2.70
Financial Health
Free Cash Flow Yield-5.01%
Growth & Risk
EPS 5Y CAGR+18.52%
FCF 5Y CAGR+37.28%
Beta (5Y)1.21
Sharpe Ratio1.49